O112 : HBsAg clearance after addition of 48 weeks of pegifn in HBeAg negative CHB patients on nucleos(T)ide therapy with undetectable hbvdna for at least one year: final results from ANRS-HB06 pegan study: multicenter randomized controlled phase III trial

0 avis

O112 : HBsAg clearance after addition of 48 weeks of pegifn in HBeAg negative CHB patients on nucleos(T)ide therapy with undetectable hbvdna for at least one year: final results from ANRS-HB06 pegan study: multicenter randomized controlled phase III trial

Archive ouverte

Edité par CCSD -

International audience. no abstract

Langue: en

Consulter en ligne

Consulter le document

Suggestions

Du même auteur

P0768 : Late mortality in treatment-experienced cirrhotic patients treated with triple therapy including boceprevir or telaprevir in a real-life cohort - ANRS Co 20 cupic

Archive ouverte | Bronowicki, J. -P. | CCSD

International audience. no abstract

LP28 : Efficacy of the oral sofosbuvir-based combinations in HCV genotype 4-mono-infected patients from the french observational cohort anrs CO22 hepather

Archive ouverte | Fontaine, H. | CCSD

International audience. Introduction:Real-life results of the Sofosbuvir (SOF)/Simeprevir(SIM) combination have been extensively reported in genotype 1-infected patients but there are few or no data regarding genoty...

LO3 : Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the french observational cohort ANRS CO22 hepather

Archive ouverte | Pol, S. | CCSD

International audience. no abstract

Chargement des enrichissements...